Clinical significance of serum soluble Fas, Fas ligand and Fas in intrahepatic lymphocytes in chronic hepatitis C

Immunological Investigations

Volumn 37, Issue 2, 2008, Pages 163-170

  Zaki, Maysaa El Sayed ^a   Auf, Fatma Abbas ^a   Ghawalby, Nabieh Anwar El ^b   Saddal, Nirmeen Mohamed El ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Chronic hepatitis C; Fas system; Intrahepatic lymphocytes

Indexed keywords

FAS ANTIGEN; FAS LIGAND; VIRUS RNA;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DAMAGE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LYMPHOCYTE; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIGENS, CD95; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED;

EID: 40049105042     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130801897352     Document Type: Article

References (23)

1. Abe, S., Kotoh, K., Arao, S, et al. (2001). Fas antigen expression on hepatocytes predicts the short and long term response to interferon therapy in patients with chronic hepatitis C. Scand J. Gastroenterol. 36:326.
2. Calabrese, F., Pontisso, P., Pettenazzo, E., et al., (2000). Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity of serum HCV-RNA levels. Hepatology 31(5):1153.
3. Feng, G., Kaplowitz, N. (2000). Dying in fast traffic. J. Clin. Invest. 105:329-334.
4. Heangy, M.L., Golde, D.W. (1996). Soluble cytokine receptors. Blood 87:847-850.
5. Hirashima, N., Matsumotoy Ohono, T., et al. (2002). Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy. J. Clin. Gastroenterol. 34(3):263-267.
6. Jiang, S., Song, M.J., Shin, E.C., et al. (1999). Apoptosis in human hepatoma cell lines chemotherapeutic drugs via fas-dependent and fas-independent pathways. Hepatology 29:101-104.
7. Kamihara, S., Yamada, Y., Tomonage, M., et al. (1999). Discrepant expression of membrane and soluble isoforms of Fas (CD95/Apo-1) in adult T- cell leukemia: soluble fas isoform is an independent factor for prognosis. Br. J. Haematol. 107:851-856.
8. Kiyici, M., Gurel, S., Budak, F., Dolar, E., Gulten, M., Nak, S.G., Memik, F. (2003). Fas antigen (CD95) expression and apoptosis in hepatocytes of patients with chronic viral hepatitis. Eur. J. Gastroenterol. Hepatol. 15(10):1079-1084.
9. Knodell, R.G., Ishak, K.G., Black, W.C., Chen, T.S., Craig, R., Caplowitz, N., Kiernan, T.W. (1981). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435.
10. Liu, X., Govindara Jan, S., Okamoto, S., et al. (2000). Fas and tumor necrosis factor receptor 1- dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. Hepatology 31(3):665.
11. Marusawah, H., Chiba, T., et al. (1999). Hepatitis C virus core protein inhibits fas and tumor necrosis factor alpha-mediated apoptosis via NF-KB activation. J. Virol. 73(6):4713.
12. Moretta A. (1997). Molecular mechanism in cell-mediated cytotoxicity. Cell 90:13-17.
13. Muschen, M., Warskulat, U., Schmidt, B., et al. (1998). Regulation of CD 95 (Apo-1/fas) ligand and receptor expression in human embryonal carcinoma cells by interferon and all transretinoic acid. Biol. Chem. 379:1083.
14. Nasir, A., Arora, H.S., Kaiser, H.E. (2000). Apoptosis and pathogenesis of viral hepatits. An update. In vitro 14:297-300.
15. Nuti, S., Rosa, D., Valiante, N.M., et al. (1998). Dynamics of intrahepatic lymphocyte in chronic hepatitis C. Enrichment for Va 24 + T cells and rapid elmination of effector cells by apoptosis. Eur. J. Immunol. 28:3448.
16. O'Brien, V. (1998). Viruses and apoptosis. J. Gen. Virol. 79:1833.
17. Papoff, G., Coscino, I., Erano, A., et al. (1996). An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol. 156:4622.
18. Pinkoski, M.J., Brunner, T., Green, D.R., et al. (2000). Fas and Fas ligand in gut and liver. A J. Gastrointestinal Liver Physiol. 278:354.
19. Raghuraman, S., Abraham, P., Daniel, H.D., Ramakrishna, B.S., Sridharan, G. (2005). Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J. Clin. Virol. 34(1):63-70.
20. Steller, H. (1995). Mechanisms and genes of cellular suicide. Science 267:1445-1449.
21. Suda, T., Nagate, S. (1994). Purification and characterization of the fas ligand that induces apoptosis. J. Exp. Med. 179:873-877.
22. Talkhan, H.A., Mabrouk, R.R., Zakaria, N.M., et al. (2000). Defective production of interferon gamma by peripheral blood T-Iympocytes and increased sFas in chronic hepatitis B infection. Egypt. J. Lab. Med. 12:69-75.
23. Teodoro, J.G., Branton, P.E. (1997). Regulation of apoptosis by viral gene products. J. Virol. 71:1739-1745.